Maxygen Inc. (NASDAQ: MAXY) said Monday its CEO and chief financial officer will leave the company on Wednesday, in keeping with a collaboration with Astellas Pharma Inc, according to Associated Press.
Wall Street Grand is a leading online financial publication. We are pleased to alert investors of stocks that are on the move.
Sign Up for our Free Stock Newsletter
James Sulat, a member of Maxygen's board of directors, will replace both CEO Russell Howard and CFO Larry Briscoe starting Oct. 1. Howard and Briscoe will enter consulting agreements with Maxygen.
On June 30, Maxygen and Astellas expanded a partnership by forming a joint venture to identify, research, and develop Maxygen's protein-based drug candidates for autoimmune diseases and transplant rejection. Maxygen contributed most of its drug candidates to the joint venture and will own 83 percent of it.
Maxygen is transferring most of its research and development operations to the joint venture, and it said Howard, Briscoe, and Chief Operating Officer and Chief Medical Officer Elliott Goldstein would likely leave the company.
Howard had been CEO since June 1998.
In aftermarket trading, Maxygen shares were unchanged at $6.84.
Sign up for Today for our free Wall Street Grand newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Wall Street Grand
Wall Street Grand is the best investor relations company on the web. From Research Reports to Stock Profiles, we give you everything you need to make the best investment decisions daily. Each of our Featured Investment Opportunities hold premium characteristics to succeed even our own expectations making us the best kept secret of Wall Street.
To feature a company on our web site please contact us at the email listed below.
Wall Street Grand's stock profiles are intended to be stock ideas, NOT recommendations. Please do your own research before investing. Please click here to read the full disclaimer.
